"We looked at potential deals but found the asking prices to be too
high for the businesses," said Sanofi Chairman Serge Weinberg.
"We have opted for a balanced a strategy of innovation and
diversification that makes acquisitions not indispensable."
The global pharmaceutical industry has been consolidating in recent
years as companies seek to replace drugs that are losing patent
protection and renew their pipeline with new products.
Through early March, M&A transactions targeting biotech and pharma
companies reached $59.3 billion this year, a 94 percent increase
over the same period a year ago and the highest volume for this
stage in any year since 2009.
(Reporting by Leila Abboud; Editing by Miral Fahmy)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |